High-performance liquid chromatographic analysis of porphyrins and their isomers with radial compression columns

Seubert, Andreas; Seubert, S.

doi:10.1016/0003-2697(82)90043-4

Cited by 56 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The supernatant was adjusted with acetic acid to pH 3-4, porphyrins were bound to talcum, esterified and metabolites were identified by HPLC with fluorescence detection (L-7480, Merck Hitachi, Darmstadt, Germany) using a porphyrin standard mixture (Porphyrin Products Inc., Logan, Utah, USA) for quantification (Seubert and Seubert, 1982). The following metabolites were analysed: protoporphyrin, tricarboxylic porphyrin, coproporphyrin, pentacarboxylic porphyrin, hexacarboxylic porphyrin, heptacarboxylic porphyrin and uroporphyrin.…”

Section: Determination Of Porphyrin Metabolites In Tissuesmentioning

confidence: 99%

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid

et al. 1999

View full text Add to dashboard Cite

Photodynamic therapy with topically applied δ-aminolaevulinic acid is used to treat skin tumours by employing endogenously formed porphyrins as photosensitizers. This study examines the time course of porphyrin metabolite formation after topical application of δ-aminolaevulinic acid. Porphyrin biosynthesis in human skin tumours (basal cell carcinoma, squamous cell carcinoma), in psoriatic lesions, and in normal skin was investigated. Skin areas were treated with δ-aminolaevulinic acid, and levels of total porphyrins, porphyrin metabolites and proteins were measured in samples excised after 1, 2, 4, 6, 9, 12 and 24 h. There was an increase in porphyrin biosynthesis in all tissues with maximum porphyrin levels in tumours between 2 and 6 h and in psoriatic lesions 6 h after treatment. The pattern of porphyrins showed no significant difference between normal and neoplastic skin, protoporphyrin being the predominant metabolite. The results suggest that optimum irradiation time for superficial epithelial skin tumours may be as soon as 2 h after application of δ-aminolaevulinic acid, whereas for treatment of psoriatic lesions an application time of 6 h is more suitable. © 1999 Cancer Research Campaign

show abstract

Section: Determination Of Porphyrin Metabolites In Tissuesmentioning

confidence: 99%

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Determination of porphyrins and their precursors was performed according to Doss and Sehmidt (1971) and Seubert and Seubert (1982). Hepatic uroporphyrinogen decarboxylase activity was determined according to San Martin de Viale et al (1977).…”

Section: Ch30~mentioning

confidence: 99%

2,2′,3′,4,4′,5,5′-Heptachlorobiphenyl (PCB 180) — on its toxicokinetics, biotransformation and porphyrinogenic action in female rats

et al. 1993

View full text Add to dashboard Cite

The toxicokinetics and biotransformation of 2,2',3',4,4',5,5'-heptachlorobiphenyl, as well as its influence on the activity of microsomal and cytosolic enzymes and on the porphyrin pathway in the liver were studied in female rats following oral treatment with 7 mg/kg every other day for 3 months. One day after cessation of treatment the concentration of the compound in liver, spleen, CNS and blood was 100-500 times and in the trachea it was only 5 times less than in the adipose tissue. The daily excretion with the feces and urine amounted to 35 and 1.5 micrograms, respectively. In both excreta, heptachlorobiphenylol was identified as a metabolite. The biotransformation rate was estimated to be about 5%. Investigations of the liver revealed increases in the relative liver weight, total cytochrome P-450 content, O-deethylation of 7-ethoxycoumarin and in the activity of glutathione S-transferases. Disturbances of the hepatic porphyrin pathway were not detected. Only at the end of a post-dosing period of 12 months did the hepatic uroporphyrinogen decarboxylase show diminished activity. Only one of these animals with diminished enzyme activity showed drastically elevated porphyrins. In these animals, the fecal and urinary porphyrins did not differ from controls. At no time did heptachlorobiphenyl influence the urinary excretion of delta-aminolevulinic acid and porphobilinogen. The results indicate 1) that this congener shows expected toxicokinetics with the exception of being accumulated in the trachea and 2) that this congener induces disturbances of the hepatic porphyrin pathway several months after cessation of treatment.

show abstract

“…Quantitative determination of urinary ALA, porphobilinogen [19] and total porphyrin excretion [20] was performed prior to and 3, 7, 14 and 28 days after onset of the treatment as well as once every 2 months after completion of the latter. Porphyrin metabolites were estimated by HPLC using a pump model 6000 A and a fluorescence detector Waters 470 (excitation at 405 nm and emission at 635 nm) with a Si60 (5-Ìm) cartridge (Merck, Germany) [21]. Additionally, in view of the neurotoxicity of thalidomide, an electrophysiological study was performed before entry and the patients were included in the study after nerve conduction and reflex studies had revealed normal values.…”

Section: Methodsmentioning

confidence: 99%

Treatment of Porphyria cutanea tarda with Oral Thalidomide

Monastirli

Georgiou²,

Bolsen³

et al. 1999

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Eight male patients with overt clinical and biochemical features of porphyria cutanea tarda (PCT) were orally treated with 300 mg/day thalidomide for 1 week and with 200 mg/day for 3 more weeks. Already after the first week of treatment no new vesicles and/or bullae could be observed. Spontaneous blisters completely disappeared, increased skin fragility subsided and skin hyperpigmentation receded about 2 months after completion of therapy, whereas hypertrichosis persisted. There was a rapid decrease in the urinary total porphyrin excretion which reached normal levels in all patients by the end of the fourth week of therapy, whereas the posttreament chromatographic pattern of urinary porphyrins revealed a slight reduction of higher carboxylated porphyrin metabolites and an increase in the amount of the excreted coproporphyrin, as compared to the pretreatment period. Somnolence, intermittent constipation and dry mouth occurred in all patients, 2 patients additionally experienced dizziness. No evidence of peripheral neuropathy could be detected and laboratory investigations revealed no abnormalities, as compared to the pretreatment period. During the 16- to 28-month follow-up of the patients, no clinical or biochemical relapse was observed. In view of the encouraging results of the present investigation, further studies are now warranted in order to definitely answer the question whether oral thalidomide may be regarded as an effective alternative approach to the treatment of PCT.

show abstract

High-performance liquid chromatographic analysis of porphyrins and their isomers with radial compression columns

Cited by 56 publications

References 20 publications

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid

2,2′,3′,4,4′,5,5′-Heptachlorobiphenyl (PCB 180) — on its toxicokinetics, biotransformation and porphyrinogenic action in female rats

Treatment of Porphyria cutanea tarda with Oral Thalidomide

Contact Info

Product

Resources

About